ArticleScientific reports2026
Identification and characterization of fibroblast-related biomarkers and pro-inflammatory subpopulations in periodontitis by integrated transcriptomic and single-cell analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is a common inflammatory disease that severely impairs oral health and may contribute to systemic complications such as cardiovascular diseases. Fibroblasts play a crucial role in the progression and repair processes of periodontitis. Exploring related biomarkers and pro-inflammatory fibroblast (PIF) subpopulations may offer potential therapeutic strategies for periodontitis. We integrated transcriptomic and single-cell RNA sequencing (scRNA-seq) data to identify hub fibroblast genes via Least Absolute Shrinkage and Selection Operator (LASSO) regression. Diagnostic models and nomograms were developed and validated based on these genes. Fibroblast molecular patterns were defined using ConsensusClusterPlus package, and pseudotime analysis was performed with Monocle package. Fibroblast-related genes (FRGs) and PIF subsets were confirmed by quantitative real-time PCR (qRT-PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH). By integrating bulk transcriptomic and single-cell RNA sequencing data, six FRGs (XBP1, SELL, ST6GAL1, IGHG1, CD79A, and PIM2) were identified using LASSO regression to construct a diagnostic model. The area under the curve (AUC) values for the model were 0.894, 0.919, and 0.746 in the GSE10334, GSE16134, and GSE173078 datasets, respectively. A predictive nomogram was also developed and validated. Based on these FRGs, periodontitis samples were clustered into three groups. Enrichment analysis revealed involvement of classical inflammatory pathways such as KRAS/p53 and IL-6/JAK/STAT. Immune infiltration analysis showed that cluster 1 exhibited a pro-inflammatory microenvironment. CXCL13⁺ fibroblasts were significantly increased in periodontitis tissues. qRT-PCR confirmed significantly elevated expression of SELL, CD79A, and ST6GAL1 in periodontitis tissues. IHC demonstrated increased SELL expression in periodontitis samples, and FISH analysis revealed a marked increase of CXCL13⁺ fibroblasts in periodontitis tissues, consistent with the bioinformatics findings. This study not only confirms the critical role of fibroblasts in periodontitis but also identifies FRGs and a PIF subset, CXCL13⁺ fibroblasts. Our findings provide novel insights into the pathogenic mechanisms of fibroblasts in periodontitis and may inform the development of targeted diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.